Compare Expedia Group Inc (EXPE) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Natera Inc. Common Stock — how do they compare? Expedia Group Inc trades at $275.51 (market cap $32.97B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is the larger of the two by market cap, and Expedia Group Inc pays a 0.7% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 47 Days and Natera Inc. Common Stock for 0 Days on average.
| EXPE | NTRA | |
|---|---|---|
Market Cap | $32.97B | $57.03B |
Volume | 1,375,250 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $425.64 |
52-Week Low | $188.51 | $179.42 |
Typical Hold Time | 47 Days | 0 Days |
Enterprise Value | $31.53B | $56.18B |
Dividend Yield | 0.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $273.44, up 1.85% with strong technical momentum above key support levels. The company demonstrates robust fundamentals with consistent earnings beats, 90% gross margins, and improving cash flow generation. Recent news highlights competitive threats from AI shopping agents but also strong B2B booking growth outpacing peers. Analyst consensus remains divided with a $335 price target representing 22% upside potential.
Expedia presents a compelling growth story with solid execution but faces significant AI disruption risks. The stock offers attractive valuation multiples and strong profitability metrics, though competitive pressures from Meta's Muse AI agent and ongoing layoffs create near-term uncertainty. Institutional positioning remains mixed with recent downgrades offset by positive earnings momentum.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
